Daxor Corporation (NASDAQ: DXR) Stock Competitors & Peer Comparison
See DXR's competitors and their performance on the NASDAQ and across the wider stock market.
Peer Comparison Table: Medical - Instruments & Supplies Industry
Detailed financial metrics including price, market cap, P/E ratio, and more for DXR and its NASDAQ peers.
| Symbol | Price | Change % | Market Cap | P/E Ratio | EPS | Dividend Yield |
|---|---|---|---|---|---|---|
| DXR | $10.45 | -2.38% | 52.7M | 27.33 | $0.38 | N/A |
| BDX | $156.36 | +2.22% | 56.6B | 11.62 | $13.45 | +2.39% |
| BDXA | $59.24 | -2.24% | 55.9B | 45.70 | $1.30 | +2.39% |
| MDLN | $38.75 | +2.98% | 32.8B | 45.06 | $0.86 | N/A |
| WST | $328.20 | -7.67% | 23.2B | 41.19 | $7.97 | +0.26% |
| HOLX | $76.01 | +0.00% | 17B | 31.54 | $2.41 | N/A |
| COO | $70.31 | +0.11% | 13.7B | 15.42 | $4.56 | N/A |
| BDXB | $48.16 | +1.39% | 13.7B | 7.60 | $6.33 | +2.39% |
| BAX | $22.40 | +3.37% | 11.6B | 10.77 | $2.08 | +0.89% |
| ATR | $132.36 | +2.61% | 8.4B | 23.13 | $5.72 | +1.43% |
Stock Comparison
Becton, Dickinson and Company (NYSE: BDX)
DXR vs BDX Comparison July 2026
Daxor Corporation (NASDAQ: DXR) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, DXR stands at 52.7M. In comparison, BDX has a market cap of 56.6B. Regarding current trading prices, DXR is priced at $10.45 on the NASDAQ, while BDX trades at $156.36.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
DXR currently has a P/E ratio of 27.33, whereas BDX's P/E ratio is 11.62. In terms of profitability, DXR's ROE is +0.22%, compared to BDX's ROE of +0.05%. Regarding short-term risk, DXR is less volatile compared to BDX. This indicates lower risk in terms of short-term price fluctuations for DXR.Check BDX's competition here
Becton, Dickinson and Company (NYSE: BDXA)
DXR vs BDXA Comparison July 2026
Daxor Corporation (NASDAQ: DXR) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, DXR stands at 52.7M. In comparison, BDXA has a market cap of 55.9B. Regarding current trading prices, DXR is priced at $10.45 on the NASDAQ, while BDXA trades at $59.24.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
DXR currently has a P/E ratio of 27.33, whereas BDXA's P/E ratio is 45.70. In terms of profitability, DXR's ROE is +0.22%, compared to BDXA's ROE of +0.05%. Regarding short-term risk, DXR is less volatile compared to BDXA. This indicates lower risk in terms of short-term price fluctuations for DXR.Check BDXA's competition here
Medline Inc. (NASDAQ: MDLN)
DXR vs MDLN Comparison July 2026
Daxor Corporation (NASDAQ: DXR) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, DXR stands at 52.7M. In comparison, MDLN has a market cap of 32.8B. Regarding current trading prices, DXR is priced at $10.45 on the NASDAQ, while MDLN trades at $38.75.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
DXR currently has a P/E ratio of 27.33, whereas MDLN's P/E ratio is 45.06. In terms of profitability, DXR's ROE is +0.22%, compared to MDLN's ROE of +0.07%. Regarding short-term risk, DXR is less volatile compared to MDLN. This indicates lower risk in terms of short-term price fluctuations for DXR.Check MDLN's competition here
West Pharmaceutical Services, Inc. (NYSE: WST)
DXR vs WST Comparison July 2026
Daxor Corporation (NASDAQ: DXR) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, DXR stands at 52.7M. In comparison, WST has a market cap of 23.2B. Regarding current trading prices, DXR is priced at $10.45 on the NASDAQ, while WST trades at $328.20.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
DXR currently has a P/E ratio of 27.33, whereas WST's P/E ratio is 41.19. In terms of profitability, DXR's ROE is +0.22%, compared to WST's ROE of +0.19%. Regarding short-term risk, DXR is less volatile compared to WST. This indicates lower risk in terms of short-term price fluctuations for DXR.Check WST's competition here
Hologic, Inc. (NASDAQ: HOLX)
DXR vs HOLX Comparison July 2026
Daxor Corporation (NASDAQ: DXR) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, DXR stands at 52.7M. In comparison, HOLX has a market cap of 17B. Regarding current trading prices, DXR is priced at $10.45 on the NASDAQ, while HOLX trades at $76.01.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
DXR currently has a P/E ratio of 27.33, whereas HOLX's P/E ratio is 31.54. In terms of profitability, DXR's ROE is +0.22%, compared to HOLX's ROE of +0.11%. Regarding short-term risk, DXR is more volatile compared to HOLX. This indicates higher risk in terms of short-term price fluctuations for DXR.Check HOLX's competition here
The Cooper Companies, Inc. (NASDAQ: COO)
DXR vs COO Comparison July 2026
Daxor Corporation (NASDAQ: DXR) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, DXR stands at 52.7M. In comparison, COO has a market cap of 13.7B. Regarding current trading prices, DXR is priced at $10.45 on the NASDAQ, while COO trades at $70.31.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
DXR currently has a P/E ratio of 27.33, whereas COO's P/E ratio is 15.42. In terms of profitability, DXR's ROE is +0.22%, compared to COO's ROE of +0.03%. Regarding short-term risk, DXR is more volatile compared to COO. This indicates higher risk in terms of short-term price fluctuations for DXR.Check COO's competition here
Becton, Dickinson and Company (NYSE: BDXB)
DXR vs BDXB Comparison July 2026
Daxor Corporation (NASDAQ: DXR) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, DXR stands at 52.7M. In comparison, BDXB has a market cap of 13.7B. Regarding current trading prices, DXR is priced at $10.45 on the NASDAQ, while BDXB trades at $48.16.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
DXR currently has a P/E ratio of 27.33, whereas BDXB's P/E ratio is 7.60. In terms of profitability, DXR's ROE is +0.22%, compared to BDXB's ROE of +0.05%. Regarding short-term risk, DXR is less volatile compared to BDXB. This indicates lower risk in terms of short-term price fluctuations for DXR.Check BDXB's competition here
Baxter International Inc. (NYSE: BAX)
DXR vs BAX Comparison July 2026
Daxor Corporation (NASDAQ: DXR) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, DXR stands at 52.7M. In comparison, BAX has a market cap of 11.6B. Regarding current trading prices, DXR is priced at $10.45 on the NASDAQ, while BAX trades at $22.40.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
DXR currently has a P/E ratio of 27.33, whereas BAX's P/E ratio is 10.77. In terms of profitability, DXR's ROE is +0.22%, compared to BAX's ROE of -0.16%. Regarding short-term risk, DXR is less volatile compared to BAX. This indicates lower risk in terms of short-term price fluctuations for DXR.Check BAX's competition here
AptarGroup, Inc. (NYSE: ATR)
DXR vs ATR Comparison July 2026
Daxor Corporation (NASDAQ: DXR) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, DXR stands at 52.7M. In comparison, ATR has a market cap of 8.4B. Regarding current trading prices, DXR is priced at $10.45 on the NASDAQ, while ATR trades at $132.36.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
DXR currently has a P/E ratio of 27.33, whereas ATR's P/E ratio is 23.13. In terms of profitability, DXR's ROE is +0.22%, compared to ATR's ROE of +0.14%. Regarding short-term risk, DXR is less volatile compared to ATR. This indicates lower risk in terms of short-term price fluctuations for DXR.Check ATR's competition here
Avantor, Inc. (NYSE: AVTR)
DXR vs AVTR Comparison July 2026
Daxor Corporation (NASDAQ: DXR) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, DXR stands at 52.7M. In comparison, AVTR has a market cap of 7.8B. Regarding current trading prices, DXR is priced at $10.45 on the NASDAQ, while AVTR trades at $11.44.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
DXR currently has a P/E ratio of 27.33, whereas AVTR's P/E ratio is 13.46. In terms of profitability, DXR's ROE is +0.22%, compared to AVTR's ROE of -0.10%. Regarding short-term risk, DXR is less volatile compared to AVTR. This indicates lower risk in terms of short-term price fluctuations for DXR.Check AVTR's competition here
Repligen Corporation (NASDAQ: RGEN)
DXR vs RGEN Comparison July 2026
Daxor Corporation (NASDAQ: DXR) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, DXR stands at 52.7M. In comparison, RGEN has a market cap of 7.4B. Regarding current trading prices, DXR is priced at $10.45 on the NASDAQ, while RGEN trades at $131.96.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
DXR currently has a P/E ratio of 27.33, whereas RGEN's P/E ratio is 73.31. In terms of profitability, DXR's ROE is +0.22%, compared to RGEN's ROE of +0.02%. Regarding short-term risk, DXR is less volatile compared to RGEN. This indicates lower risk in terms of short-term price fluctuations for DXR.Check RGEN's competition here
Teleflex Incorporated (NYSE: TFX)
DXR vs TFX Comparison July 2026
Daxor Corporation (NASDAQ: DXR) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, DXR stands at 52.7M. In comparison, TFX has a market cap of 5.8B. Regarding current trading prices, DXR is priced at $10.45 on the NASDAQ, while TFX trades at $132.10.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
DXR currently has a P/E ratio of 27.33, whereas TFX's P/E ratio is 12.32. In terms of profitability, DXR's ROE is +0.22%, compared to TFX's ROE of -0.28%. Regarding short-term risk, DXR is less volatile compared to TFX. This indicates lower risk in terms of short-term price fluctuations for DXR.Check TFX's competition here
Bausch + Lomb Corporation (NYSE: BLCO)
DXR vs BLCO Comparison July 2026
Daxor Corporation (NASDAQ: DXR) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, DXR stands at 52.7M. In comparison, BLCO has a market cap of 5.8B. Regarding current trading prices, DXR is priced at $10.45 on the NASDAQ, while BLCO trades at $16.17.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
DXR currently has a P/E ratio of 27.33, whereas BLCO's P/E ratio is 24.88. In terms of profitability, DXR's ROE is +0.22%, compared to BLCO's ROE of -0.03%. Regarding short-term risk, DXR is less volatile compared to BLCO. This indicates lower risk in terms of short-term price fluctuations for DXR.Check BLCO's competition here
Stevanato Group S.p.A. (NYSE: STVN)
DXR vs STVN Comparison July 2026
Daxor Corporation (NASDAQ: DXR) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, DXR stands at 52.7M. In comparison, STVN has a market cap of 5.4B. Regarding current trading prices, DXR is priced at $10.45 on the NASDAQ, while STVN trades at $19.68.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
DXR currently has a P/E ratio of 27.33, whereas STVN's P/E ratio is 31.81. In terms of profitability, DXR's ROE is +0.22%, compared to STVN's ROE of +0.10%. Regarding short-term risk, DXR is less volatile compared to STVN. This indicates lower risk in terms of short-term price fluctuations for DXR.Check STVN's competition here
Merit Medical Systems, Inc. (NASDAQ: MMSI)
DXR vs MMSI Comparison July 2026
Daxor Corporation (NASDAQ: DXR) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, DXR stands at 52.7M. In comparison, MMSI has a market cap of 4.4B. Regarding current trading prices, DXR is priced at $10.45 on the NASDAQ, while MMSI trades at $74.32.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
DXR currently has a P/E ratio of 27.33, whereas MMSI's P/E ratio is 19.01. In terms of profitability, DXR's ROE is +0.22%, compared to MMSI's ROE of +0.09%. Regarding short-term risk, DXR is less volatile compared to MMSI. This indicates lower risk in terms of short-term price fluctuations for DXR.Check MMSI's competition here
ICU Medical, Inc. (NASDAQ: ICUI)
DXR vs ICUI Comparison July 2026
Daxor Corporation (NASDAQ: DXR) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, DXR stands at 52.7M. In comparison, ICUI has a market cap of 3.9B. Regarding current trading prices, DXR is priced at $10.45 on the NASDAQ, while ICUI trades at $157.44.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
DXR currently has a P/E ratio of 27.33, whereas ICUI's P/E ratio is 19.66. In terms of profitability, DXR's ROE is +0.22%, compared to ICUI's ROE of +0.02%. Regarding short-term risk, DXR is less volatile compared to ICUI. This indicates lower risk in terms of short-term price fluctuations for DXR.Check ICUI's competition here
Haemonetics Corporation (NYSE: HAE)
DXR vs HAE Comparison July 2026
Daxor Corporation (NASDAQ: DXR) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, DXR stands at 52.7M. In comparison, HAE has a market cap of 3.6B. Regarding current trading prices, DXR is priced at $10.45 on the NASDAQ, while HAE trades at $78.78.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
DXR currently has a P/E ratio of 27.33, whereas HAE's P/E ratio is 15.86. In terms of profitability, DXR's ROE is +0.22%, compared to HAE's ROE of +0.11%. Regarding short-term risk, DXR is less volatile compared to HAE. This indicates lower risk in terms of short-term price fluctuations for DXR.Check HAE's competition here
DENTSPLY SIRONA Inc. (NASDAQ: XRAY)
DXR vs XRAY Comparison July 2026
Daxor Corporation (NASDAQ: DXR) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, DXR stands at 52.7M. In comparison, XRAY has a market cap of 2.6B. Regarding current trading prices, DXR is priced at $10.45 on the NASDAQ, while XRAY trades at $12.93.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
DXR currently has a P/E ratio of 27.33, whereas XRAY's P/E ratio is 9.04. In terms of profitability, DXR's ROE is +0.22%, compared to XRAY's ROE of -0.41%. Regarding short-term risk, DXR is less volatile compared to XRAY. This indicates lower risk in terms of short-term price fluctuations for DXR.Check XRAY's competition here
LeMaitre Vascular, Inc. (NASDAQ: LMAT)
DXR vs LMAT Comparison July 2026
Daxor Corporation (NASDAQ: DXR) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, DXR stands at 52.7M. In comparison, LMAT has a market cap of 2.2B. Regarding current trading prices, DXR is priced at $10.45 on the NASDAQ, while LMAT trades at $95.59.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
DXR currently has a P/E ratio of 27.33, whereas LMAT's P/E ratio is 37.05. In terms of profitability, DXR's ROE is +0.22%, compared to LMAT's ROE of +0.16%. Regarding short-term risk, DXR is less volatile compared to LMAT. This indicates lower risk in terms of short-term price fluctuations for DXR.Check LMAT's competition here
Pulse Biosciences, Inc. (NASDAQ: PLSE)
DXR vs PLSE Comparison July 2026
Daxor Corporation (NASDAQ: DXR) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, DXR stands at 52.7M. In comparison, PLSE has a market cap of 2.1B. Regarding current trading prices, DXR is priced at $10.45 on the NASDAQ, while PLSE trades at $30.23.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
DXR currently has a P/E ratio of 27.33, whereas PLSE's P/E ratio is -27.48. In terms of profitability, DXR's ROE is +0.22%, compared to PLSE's ROE of -0.87%. Regarding short-term risk, DXR is less volatile compared to PLSE. This indicates lower risk in terms of short-term price fluctuations for DXR.Check PLSE's competition here
AtriCure, Inc. (NASDAQ: ATRC)
DXR vs ATRC Comparison July 2026
Daxor Corporation (NASDAQ: DXR) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, DXR stands at 52.7M. In comparison, ATRC has a market cap of 1.8B. Regarding current trading prices, DXR is priced at $10.45 on the NASDAQ, while ATRC trades at $35.04.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
DXR currently has a P/E ratio of 27.33, whereas ATRC's P/E ratio is 1088.20. In terms of profitability, DXR's ROE is +0.22%, compared to ATRC's ROE of +0.02%. Regarding short-term risk, DXR is less volatile compared to ATRC. This indicates lower risk in terms of short-term price fluctuations for DXR.Check ATRC's competition here
BioLife Solutions, Inc. (NASDAQ: BLFS)
DXR vs BLFS Comparison July 2026
Daxor Corporation (NASDAQ: DXR) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, DXR stands at 52.7M. In comparison, BLFS has a market cap of 1.5B. Regarding current trading prices, DXR is priced at $10.45 on the NASDAQ, while BLFS trades at $29.98.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
DXR currently has a P/E ratio of 27.33, whereas BLFS's P/E ratio is -141.85. In terms of profitability, DXR's ROE is +0.22%, compared to BLFS's ROE of -0.03%. Regarding short-term risk, DXR is less volatile compared to BLFS. This indicates lower risk in terms of short-term price fluctuations for DXR.Check BLFS's competition here
Azenta, Inc. (NASDAQ: AZTA)
DXR vs AZTA Comparison July 2026
Daxor Corporation (NASDAQ: DXR) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, DXR stands at 52.7M. In comparison, AZTA has a market cap of 1.3B. Regarding current trading prices, DXR is priced at $10.45 on the NASDAQ, while AZTA trades at $27.37.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
DXR currently has a P/E ratio of 27.33, whereas AZTA's P/E ratio is 60.82. In terms of profitability, DXR's ROE is +0.22%, compared to AZTA's ROE of -0.11%. Regarding short-term risk, DXR is less volatile compared to AZTA. This indicates lower risk in terms of short-term price fluctuations for DXR.Check AZTA's competition here
Kestra Medical Technologies, Ltd. (NASDAQ: KMTS)
DXR vs KMTS Comparison July 2026
Daxor Corporation (NASDAQ: DXR) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, DXR stands at 52.7M. In comparison, KMTS has a market cap of 1.2B. Regarding current trading prices, DXR is priced at $10.45 on the NASDAQ, while KMTS trades at $21.06.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
DXR currently has a P/E ratio of 27.33, whereas KMTS's P/E ratio is -8.92. In terms of profitability, DXR's ROE is +0.22%, compared to KMTS's ROE of -0.59%. Regarding short-term risk, DXR is less volatile compared to KMTS. This indicates lower risk in terms of short-term price fluctuations for DXR.Check KMTS's competition here
STAAR Surgical Company (NASDAQ: STAA)
DXR vs STAA Comparison July 2026
Daxor Corporation (NASDAQ: DXR) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, DXR stands at 52.7M. In comparison, STAA has a market cap of 1.2B. Regarding current trading prices, DXR is priced at $10.45 on the NASDAQ, while STAA trades at $23.38.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
DXR currently has a P/E ratio of 27.33, whereas STAA's P/E ratio is 41.02. In terms of profitability, DXR's ROE is +0.22%, compared to STAA's ROE of -0.06%. Regarding short-term risk, DXR is less volatile compared to STAA. This indicates lower risk in terms of short-term price fluctuations for DXR.Check STAA's competition here
QuidelOrtho Corporation (NASDAQ: QDEL)
DXR vs QDEL Comparison July 2026
Daxor Corporation (NASDAQ: DXR) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, DXR stands at 52.7M. In comparison, QDEL has a market cap of 1.1B. Regarding current trading prices, DXR is priced at $10.45 on the NASDAQ, while QDEL trades at $16.05.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
DXR currently has a P/E ratio of 27.33, whereas QDEL's P/E ratio is 11.98. In terms of profitability, DXR's ROE is +0.22%, compared to QDEL's ROE of -0.56%. Regarding short-term risk, DXR is less volatile compared to QDEL. This indicates lower risk in terms of short-term price fluctuations for DXR.Check QDEL's competition here
Atrion Corporation (NASDAQ: ATRI)
DXR vs ATRI Comparison July 2026
Daxor Corporation (NASDAQ: DXR) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, DXR stands at 52.7M. In comparison, ATRI has a market cap of 809.4M. Regarding current trading prices, DXR is priced at $10.45 on the NASDAQ, while ATRI trades at $459.92.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
DXR currently has a P/E ratio of 27.33, whereas ATRI's P/E ratio is 64.50. In terms of profitability, DXR's ROE is +0.22%, compared to ATRI's ROE of +0.08%. Regarding short-term risk, DXR is more volatile compared to ATRI. This indicates higher risk in terms of short-term price fluctuations for DXR.Check ATRI's competition here
AngioDynamics, Inc. (NASDAQ: ANGO)
DXR vs ANGO Comparison July 2026
Daxor Corporation (NASDAQ: DXR) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, DXR stands at 52.7M. In comparison, ANGO has a market cap of 561.7M. Regarding current trading prices, DXR is priced at $10.45 on the NASDAQ, while ANGO trades at $13.59.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
DXR currently has a P/E ratio of 27.33, whereas ANGO's P/E ratio is -34.85. In terms of profitability, DXR's ROE is +0.22%, compared to ANGO's ROE of -0.21%. Regarding short-term risk, DXR is less volatile compared to ANGO. This indicates lower risk in terms of short-term price fluctuations for DXR.Check ANGO's competition here
Anbio Biotechnology Class A Ordinary Shares (NASDAQ: NNNN)
DXR vs NNNN Comparison July 2026
Daxor Corporation (NASDAQ: DXR) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, DXR stands at 52.7M. In comparison, NNNN has a market cap of 441.5M. Regarding current trading prices, DXR is priced at $10.45 on the NASDAQ, while NNNN trades at $9.90.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
DXR currently has a P/E ratio of 27.33, whereas NNNN's P/E ratio is 145.38. In terms of profitability, DXR's ROE is +0.22%, compared to NNNN's ROE of +0.27%. Regarding short-term risk, DXR is less volatile compared to NNNN. This indicates lower risk in terms of short-term price fluctuations for DXR.Check NNNN's competition here
OraSure Technologies, Inc. (NASDAQ: OSUR)
DXR vs OSUR Comparison July 2026
Daxor Corporation (NASDAQ: DXR) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, DXR stands at 52.7M. In comparison, OSUR has a market cap of 273.3M. Regarding current trading prices, DXR is priced at $10.45 on the NASDAQ, while OSUR trades at $3.97.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
DXR currently has a P/E ratio of 27.33, whereas OSUR's P/E ratio is -4.78. In terms of profitability, DXR's ROE is +0.22%, compared to OSUR's ROE of -0.21%. Regarding short-term risk, DXR is less volatile compared to OSUR. This indicates lower risk in terms of short-term price fluctuations for DXR.Check OSUR's competition here
Sanara MedTech Inc. (NASDAQ: SMTI)
DXR vs SMTI Comparison July 2026
Daxor Corporation (NASDAQ: DXR) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, DXR stands at 52.7M. In comparison, SMTI has a market cap of 234.2M. Regarding current trading prices, DXR is priced at $10.45 on the NASDAQ, while SMTI trades at $25.56.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
DXR currently has a P/E ratio of 27.33, whereas SMTI's P/E ratio is -426.00. In terms of profitability, DXR's ROE is +0.22%, compared to SMTI's ROE of -2.46%. Regarding short-term risk, DXR is less volatile compared to SMTI. This indicates lower risk in terms of short-term price fluctuations for DXR.Check SMTI's competition here
Utah Medical Products, Inc. (NASDAQ: UTMD)
DXR vs UTMD Comparison July 2026
Daxor Corporation (NASDAQ: DXR) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, DXR stands at 52.7M. In comparison, UTMD has a market cap of 213.8M. Regarding current trading prices, DXR is priced at $10.45 on the NASDAQ, while UTMD trades at $67.14.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
DXR currently has a P/E ratio of 27.33, whereas UTMD's P/E ratio is 19.86. In terms of profitability, DXR's ROE is +0.22%, compared to UTMD's ROE of +0.09%. Regarding short-term risk, DXR is less volatile compared to UTMD. This indicates lower risk in terms of short-term price fluctuations for DXR.Check UTMD's competition here
InfuSystem Holdings, Inc. (AMEX: INFU)
DXR vs INFU Comparison July 2026
Daxor Corporation (NASDAQ: DXR) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, DXR stands at 52.7M. In comparison, INFU has a market cap of 183.9M. Regarding current trading prices, DXR is priced at $10.45 on the NASDAQ, while INFU trades at $9.12.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
DXR currently has a P/E ratio of 27.33, whereas INFU's P/E ratio is 23.97. In terms of profitability, DXR's ROE is +0.22%, compared to INFU's ROE of +0.14%. Regarding short-term risk, DXR is less volatile compared to INFU. This indicates lower risk in terms of short-term price fluctuations for DXR.Check INFU's competition here
KORU Medical Systems, Inc. (NASDAQ: KRMD)
DXR vs KRMD Comparison July 2026
Daxor Corporation (NASDAQ: DXR) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, DXR stands at 52.7M. In comparison, KRMD has a market cap of 175.9M. Regarding current trading prices, DXR is priced at $10.45 on the NASDAQ, while KRMD trades at $3.83.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
DXR currently has a P/E ratio of 27.33, whereas KRMD's P/E ratio is -95.75. In terms of profitability, DXR's ROE is +0.22%, compared to KRMD's ROE of -0.14%. Regarding short-term risk, DXR is less volatile compared to KRMD. This indicates lower risk in terms of short-term price fluctuations for DXR.Check KRMD's competition here
Pro-Dex, Inc. (NASDAQ: PDEX)
DXR vs PDEX Comparison July 2026
Daxor Corporation (NASDAQ: DXR) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, DXR stands at 52.7M. In comparison, PDEX has a market cap of 175.4M. Regarding current trading prices, DXR is priced at $10.45 on the NASDAQ, while PDEX trades at $54.93.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
DXR currently has a P/E ratio of 27.33, whereas PDEX's P/E ratio is 19.34. In terms of profitability, DXR's ROE is +0.22%, compared to PDEX's ROE of +0.29%. Regarding short-term risk, DXR is less volatile compared to PDEX. This indicates lower risk in terms of short-term price fluctuations for DXR.Check PDEX's competition here
Microbot Medical Inc. (NASDAQ: MBOT)
DXR vs MBOT Comparison July 2026
Daxor Corporation (NASDAQ: DXR) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, DXR stands at 52.7M. In comparison, MBOT has a market cap of 77.9M. Regarding current trading prices, DXR is priced at $10.45 on the NASDAQ, while MBOT trades at $1.71.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
DXR currently has a P/E ratio of 27.33, whereas MBOT's P/E ratio is -6.58. In terms of profitability, DXR's ROE is +0.22%, compared to MBOT's ROE of -0.22%. Regarding short-term risk, DXR is less volatile compared to MBOT. This indicates lower risk in terms of short-term price fluctuations for DXR.Check MBOT's competition here
Akoya Biosciences, Inc. (NASDAQ: AKYA)
DXR vs AKYA Comparison July 2026
Daxor Corporation (NASDAQ: DXR) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, DXR stands at 52.7M. In comparison, AKYA has a market cap of 64.4M. Regarding current trading prices, DXR is priced at $10.45 on the NASDAQ, while AKYA trades at $1.29.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
DXR currently has a P/E ratio of 27.33, whereas AKYA's P/E ratio is -1.34. In terms of profitability, DXR's ROE is +0.22%, compared to AKYA's ROE of -1.80%. Regarding short-term risk, DXR is more volatile compared to AKYA. This indicates higher risk in terms of short-term price fluctuations for DXR.Check AKYA's competition here
SkyAI, Inc. (NASDAQ: STSS)
DXR vs STSS Comparison July 2026
Daxor Corporation (NASDAQ: DXR) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, DXR stands at 52.7M. In comparison, STSS has a market cap of 58.4M. Regarding current trading prices, DXR is priced at $10.45 on the NASDAQ, while STSS trades at $1.39.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
DXR currently has a P/E ratio of 27.33, whereas STSS's P/E ratio is -0.02. In terms of profitability, DXR's ROE is +0.22%, compared to STSS's ROE of -1.66%. Regarding short-term risk, DXR is less volatile compared to STSS. This indicates lower risk in terms of short-term price fluctuations for DXR.Check STSS's competition here
Singular Genomics Systems, Inc. (NASDAQ: OMIC)
DXR vs OMIC Comparison July 2026
Daxor Corporation (NASDAQ: DXR) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, DXR stands at 52.7M. In comparison, OMIC has a market cap of 50.8M. Regarding current trading prices, DXR is priced at $10.45 on the NASDAQ, while OMIC trades at $20.01.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
DXR currently has a P/E ratio of 27.33, whereas OMIC's P/E ratio is -0.58. In terms of profitability, DXR's ROE is +0.22%, compared to OMIC's ROE of -0.43%. Regarding short-term risk, DXR is more volatile compared to OMIC. This indicates higher risk in terms of short-term price fluctuations for DXR.Check OMIC's competition here
GlucoTrack, Inc. (NASDAQ: IGAP)
DXR vs IGAP Comparison July 2026
Daxor Corporation (NASDAQ: DXR) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, DXR stands at 52.7M. In comparison, IGAP has a market cap of 50.2M. Regarding current trading prices, DXR is priced at $10.45 on the NASDAQ, while IGAP trades at $3.24.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
DXR currently has a P/E ratio of 27.33, whereas IGAP's P/E ratio is -10.52. In terms of profitability, DXR's ROE is +0.22%, compared to IGAP's ROE of -0.86%. Regarding short-term risk, DXR is less volatile compared to IGAP. This indicates lower risk in terms of short-term price fluctuations for DXR.Check IGAP's competition here
Nephros, Inc. (NASDAQ: NEPH)
DXR vs NEPH Comparison July 2026
Daxor Corporation (NASDAQ: DXR) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, DXR stands at 52.7M. In comparison, NEPH has a market cap of 38.6M. Regarding current trading prices, DXR is priced at $10.45 on the NASDAQ, while NEPH trades at $3.64.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
DXR currently has a P/E ratio of 27.33, whereas NEPH's P/E ratio is 50.86. In terms of profitability, DXR's ROE is +0.22%, compared to NEPH's ROE of +0.08%. Regarding short-term risk, DXR is less volatile compared to NEPH. This indicates lower risk in terms of short-term price fluctuations for DXR.Check NEPH's competition here
Milestone Scientific Inc. (AMEX: MLSS)
DXR vs MLSS Comparison July 2026
Daxor Corporation (NASDAQ: DXR) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, DXR stands at 52.7M. In comparison, MLSS has a market cap of 34.5M. Regarding current trading prices, DXR is priced at $10.45 on the NASDAQ, while MLSS trades at $0.39.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
DXR currently has a P/E ratio of 27.33, whereas MLSS's P/E ratio is -6.50. In terms of profitability, DXR's ROE is +0.22%, compared to MLSS's ROE of -1.66%. Regarding short-term risk, DXR is less volatile compared to MLSS. This indicates lower risk in terms of short-term price fluctuations for DXR.Check MLSS's competition here
Precision Optics Corporation, Inc. (NASDAQ: POCI)
DXR vs POCI Comparison July 2026
Daxor Corporation (NASDAQ: DXR) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, DXR stands at 52.7M. In comparison, POCI has a market cap of 33.8M. Regarding current trading prices, DXR is priced at $10.45 on the NASDAQ, while POCI trades at $4.30.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
DXR currently has a P/E ratio of 27.33, whereas POCI's P/E ratio is -6.07. In terms of profitability, DXR's ROE is +0.22%, compared to POCI's ROE of -0.37%. Regarding short-term risk, DXR is less volatile compared to POCI. This indicates lower risk in terms of short-term price fluctuations for DXR.Check POCI's competition here
SmileDirectClub, Inc. (NASDAQ: SDC)
DXR vs SDC Comparison July 2026
Daxor Corporation (NASDAQ: DXR) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, DXR stands at 52.7M. In comparison, SDC has a market cap of 29.1M. Regarding current trading prices, DXR is priced at $10.45 on the NASDAQ, while SDC trades at $0.08.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
DXR currently has a P/E ratio of 27.33, whereas SDC's P/E ratio is -0.03. In terms of profitability, DXR's ROE is +0.22%, compared to SDC's ROE of -1.96%. Regarding short-term risk, DXR is less volatile compared to SDC. This indicates lower risk in terms of short-term price fluctuations for DXR.Check SDC's competition here
Harvard Bioscience, Inc. (NASDAQ: HBIO)
DXR vs HBIO Comparison July 2026
Daxor Corporation (NASDAQ: DXR) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, DXR stands at 52.7M. In comparison, HBIO has a market cap of 27.3M. Regarding current trading prices, DXR is priced at $10.45 on the NASDAQ, while HBIO trades at $6.00.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
DXR currently has a P/E ratio of 27.33, whereas HBIO's P/E ratio is -16.81. In terms of profitability, DXR's ROE is +0.22%, compared to HBIO's ROE of -0.73%. Regarding short-term risk, DXR is less volatile compared to HBIO. This indicates lower risk in terms of short-term price fluctuations for DXR.Check HBIO's competition here
Invacare Corporation (NYSE: IVC)
DXR vs IVC Comparison July 2026
Daxor Corporation (NASDAQ: DXR) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, DXR stands at 52.7M. In comparison, IVC has a market cap of 24.9M. Regarding current trading prices, DXR is priced at $10.45 on the NASDAQ, while IVC trades at $0.66.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
DXR currently has a P/E ratio of 27.33, whereas IVC's P/E ratio is -0.79. In terms of profitability, DXR's ROE is +0.22%, compared to IVC's ROE of -0.46%. Regarding short-term risk, DXR is less volatile compared to IVC. This indicates lower risk in terms of short-term price fluctuations for DXR.Check IVC's competition here
Retractable Technologies, Inc. (AMEX: RVP)
DXR vs RVP Comparison July 2026
Daxor Corporation (NASDAQ: DXR) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, DXR stands at 52.7M. In comparison, RVP has a market cap of 20.4M. Regarding current trading prices, DXR is priced at $10.45 on the NASDAQ, while RVP trades at $0.68.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
DXR currently has a P/E ratio of 27.33, whereas RVP's P/E ratio is -2.06. In terms of profitability, DXR's ROE is +0.22%, compared to RVP's ROE of -0.08%. Regarding short-term risk, DXR is more volatile compared to RVP. This indicates higher risk in terms of short-term price fluctuations for DXR.Check RVP's competition here
Jin Medical International Ltd. (NASDAQ: ZJYL)
DXR vs ZJYL Comparison July 2026
Daxor Corporation (NASDAQ: DXR) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, DXR stands at 52.7M. In comparison, ZJYL has a market cap of 16M. Regarding current trading prices, DXR is priced at $10.45 on the NASDAQ, while ZJYL trades at $2.06.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
DXR currently has a P/E ratio of 27.33, whereas ZJYL's P/E ratio is 12.75. In terms of profitability, DXR's ROE is +0.22%, compared to ZJYL's ROE of +0.04%. Regarding short-term risk, DXR is less volatile compared to ZJYL. This indicates lower risk in terms of short-term price fluctuations for DXR.Check ZJYL's competition here
Femasys Inc. (NASDAQ: FEMY)
DXR vs FEMY Comparison July 2026
Daxor Corporation (NASDAQ: DXR) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, DXR stands at 52.7M. In comparison, FEMY has a market cap of 11.2M. Regarding current trading prices, DXR is priced at $10.45 on the NASDAQ, while FEMY trades at $3.71.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
DXR currently has a P/E ratio of 27.33, whereas FEMY's P/E ratio is -10.25. In terms of profitability, DXR's ROE is +0.22%, compared to FEMY's ROE of -2.58%. Regarding short-term risk, DXR is less volatile compared to FEMY. This indicates lower risk in terms of short-term price fluctuations for DXR.Check FEMY's competition here
Regentis Biomaterials Ltd. (AMEX: RGNT)
DXR vs RGNT Comparison July 2026
Daxor Corporation (NASDAQ: DXR) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, DXR stands at 52.7M. In comparison, RGNT has a market cap of 7.8M. Regarding current trading prices, DXR is priced at $10.45 on the NASDAQ, while RGNT trades at $1.96.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
DXR currently has a P/E ratio of 27.33, whereas RGNT's P/E ratio is -0.08. In terms of profitability, DXR's ROE is +0.22%, compared to RGNT's ROE of N/A. Regarding short-term risk, DXR is less volatile compared to RGNT. This indicates lower risk in terms of short-term price fluctuations for DXR.Check RGNT's competition here
NanoString Technologies, Inc. (NASDAQ: NSTG)
DXR vs NSTG Comparison July 2026
Daxor Corporation (NASDAQ: DXR) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, DXR stands at 52.7M. In comparison, NSTG has a market cap of 5.1M. Regarding current trading prices, DXR is priced at $10.45 on the NASDAQ, while NSTG trades at $0.11.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
DXR currently has a P/E ratio of 27.33, whereas NSTG's P/E ratio is -0.03. In terms of profitability, DXR's ROE is +0.22%, compared to NSTG's ROE of -1.43%. Regarding short-term risk, DXR is less volatile compared to NSTG. This indicates lower risk in terms of short-term price fluctuations for DXR.Check NSTG's competition here
NEXGEL, Inc. (NASDAQ: NXGL)
DXR vs NXGL Comparison July 2026
Daxor Corporation (NASDAQ: DXR) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, DXR stands at 52.7M. In comparison, NXGL has a market cap of 4M. Regarding current trading prices, DXR is priced at $10.45 on the NASDAQ, while NXGL trades at $0.44.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
DXR currently has a P/E ratio of 27.33, whereas NXGL's P/E ratio is -1.13. In terms of profitability, DXR's ROE is +0.22%, compared to NXGL's ROE of -0.70%. Regarding short-term risk, DXR is less volatile compared to NXGL. This indicates lower risk in terms of short-term price fluctuations for DXR.Check NXGL's competition here
Predictive Oncology Inc. (NASDAQ: POAI)
DXR vs POAI Comparison July 2026
Daxor Corporation (NASDAQ: DXR) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, DXR stands at 52.7M. In comparison, POAI has a market cap of 3.6M. Regarding current trading prices, DXR is priced at $10.45 on the NASDAQ, while POAI trades at $4.91.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
DXR currently has a P/E ratio of 27.33, whereas POAI's P/E ratio is -0.03. In terms of profitability, DXR's ROE is +0.22%, compared to POAI's ROE of -107.05%. Regarding short-term risk, DXR is less volatile compared to POAI. This indicates lower risk in terms of short-term price fluctuations for DXR.Check POAI's competition here
Lucyd, Inc (NASDAQ: LUCY)
DXR vs LUCY Comparison July 2026
Daxor Corporation (NASDAQ: DXR) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, DXR stands at 52.7M. In comparison, LUCY has a market cap of 2.6M. Regarding current trading prices, DXR is priced at $10.45 on the NASDAQ, while LUCY trades at $0.65.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
DXR currently has a P/E ratio of 27.33, whereas LUCY's P/E ratio is -0.39. In terms of profitability, DXR's ROE is +0.22%, compared to LUCY's ROE of -0.83%. Regarding short-term risk, DXR is less volatile compared to LUCY. This indicates lower risk in terms of short-term price fluctuations for DXR.Check LUCY's competition here
Meihua International Medical Technologies Co., Ltd. (NASDAQ: MHUA)
DXR vs MHUA Comparison July 2026
Daxor Corporation (NASDAQ: DXR) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, DXR stands at 52.7M. In comparison, MHUA has a market cap of 2.4M. Regarding current trading prices, DXR is priced at $10.45 on the NASDAQ, while MHUA trades at $7.61.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
DXR currently has a P/E ratio of 27.33, whereas MHUA's P/E ratio is 0.25. In terms of profitability, DXR's ROE is +0.22%, compared to MHUA's ROE of +0.07%. Regarding short-term risk, DXR is more volatile compared to MHUA. This indicates higher risk in terms of short-term price fluctuations for DXR.Check MHUA's competition here
NEXGEL, Inc. (NASDAQ: NXGLW)
DXR vs NXGLW Comparison July 2026
Daxor Corporation (NASDAQ: DXR) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, DXR stands at 52.7M. In comparison, NXGLW has a market cap of 1.8M. Regarding current trading prices, DXR is priced at $10.45 on the NASDAQ, while NXGLW trades at $0.02.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
DXR currently has a P/E ratio of 27.33, whereas NXGLW's P/E ratio is -0.06. In terms of profitability, DXR's ROE is +0.22%, compared to NXGLW's ROE of -0.70%. Regarding short-term risk, DXR is more volatile compared to NXGLW. This indicates higher risk in terms of short-term price fluctuations for DXR.Check NXGLW's competition here
G Medical Innovations Holdings Ltd (NASDAQ: GMVD)
DXR vs GMVD Comparison July 2026
Daxor Corporation (NASDAQ: DXR) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, DXR stands at 52.7M. In comparison, GMVD has a market cap of 1.8M. Regarding current trading prices, DXR is priced at $10.45 on the NASDAQ, while GMVD trades at $0.18.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
DXR currently has a P/E ratio of 27.33, whereas GMVD's P/E ratio is -0.01. In terms of profitability, DXR's ROE is +0.22%, compared to GMVD's ROE of +2.09%. Regarding short-term risk, DXR is less volatile compared to GMVD. This indicates lower risk in terms of short-term price fluctuations for DXR.Check GMVD's competition here
G Medical Innovations Holdings Ltd (NASDAQ: GMVDW)
DXR vs GMVDW Comparison July 2026
Daxor Corporation (NASDAQ: DXR) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, DXR stands at 52.7M. In comparison, GMVDW has a market cap of 1.8M. Regarding current trading prices, DXR is priced at $10.45 on the NASDAQ, while GMVDW trades at $7.04.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
DXR currently has a P/E ratio of 27.33, whereas GMVDW's P/E ratio is N/A. In terms of profitability, DXR's ROE is +0.22%, compared to GMVDW's ROE of +2.09%. Regarding short-term risk, DXR is less volatile compared to GMVDW. This indicates lower risk in terms of short-term price fluctuations for DXR.Check GMVDW's competition here
Avinger, Inc. (NASDAQ: AVGR)
DXR vs AVGR Comparison July 2026
Daxor Corporation (NASDAQ: DXR) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, DXR stands at 52.7M. In comparison, AVGR has a market cap of 1.5M. Regarding current trading prices, DXR is priced at $10.45 on the NASDAQ, while AVGR trades at $0.47.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
DXR currently has a P/E ratio of 27.33, whereas AVGR's P/E ratio is -0.05. In terms of profitability, DXR's ROE is +0.22%, compared to AVGR's ROE of +17.82%. Regarding short-term risk, DXR is less volatile compared to AVGR. This indicates lower risk in terms of short-term price fluctuations for DXR.Check AVGR's competition here
Lucyd, Inc (NASDAQ: LUCYW)
DXR vs LUCYW Comparison July 2026
Daxor Corporation (NASDAQ: DXR) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, DXR stands at 52.7M. In comparison, LUCYW has a market cap of 296.1K. Regarding current trading prices, DXR is priced at $10.45 on the NASDAQ, while LUCYW trades at $0.06.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
DXR currently has a P/E ratio of 27.33, whereas LUCYW's P/E ratio is -0.00. In terms of profitability, DXR's ROE is +0.22%, compared to LUCYW's ROE of -0.83%. Regarding short-term risk, DXR is less volatile compared to LUCYW. This indicates lower risk in terms of short-term price fluctuations for DXR.Check LUCYW's competition here
GlucoTrack, Inc. (NASDAQ: GCTK)
DXR vs GCTK Comparison July 2026
Daxor Corporation (NASDAQ: DXR) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, DXR stands at 52.7M. In comparison, GCTK has a market cap of 165.2K. Regarding current trading prices, DXR is priced at $10.45 on the NASDAQ, while GCTK trades at $0.29.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
DXR currently has a P/E ratio of 27.33, whereas GCTK's P/E ratio is -0.01. In terms of profitability, DXR's ROE is +0.22%, compared to GCTK's ROE of -5.82%. Regarding short-term risk, DXR is less volatile compared to GCTK. This indicates lower risk in terms of short-term price fluctuations for DXR.Check GCTK's competition here
Apria, Inc. (NASDAQ: APR)
DXR vs APR Comparison July 2026
Daxor Corporation (NASDAQ: DXR) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, DXR stands at 52.7M. In comparison, APR has a market cap of 0. Regarding current trading prices, DXR is priced at $10.45 on the NASDAQ, while APR trades at $37.50.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
DXR currently has a P/E ratio of 27.33, whereas APR's P/E ratio is 22.59. In terms of profitability, DXR's ROE is +0.22%, compared to APR's ROE of +9.81%. Regarding short-term risk, DXR is more volatile compared to APR. This indicates higher risk in terms of short-term price fluctuations for DXR.Check APR's competition here
IntriCon Corporation (NASDAQ: IIN)
DXR vs IIN Comparison July 2026
Daxor Corporation (NASDAQ: DXR) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, DXR stands at 52.7M. In comparison, IIN has a market cap of 0. Regarding current trading prices, DXR is priced at $10.45 on the NASDAQ, while IIN trades at $24.23.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
DXR currently has a P/E ratio of 27.33, whereas IIN's P/E ratio is 226.45. In terms of profitability, DXR's ROE is +0.22%, compared to IIN's ROE of -0.00%. Regarding short-term risk, DXR is more volatile compared to IIN. This indicates higher risk in terms of short-term price fluctuations for DXR.Check IIN's competition here
Hill-Rom Holdings, Inc. (NYSE: HRC)
DXR vs HRC Comparison July 2026
Daxor Corporation (NASDAQ: DXR) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, DXR stands at 52.7M. In comparison, HRC has a market cap of 0. Regarding current trading prices, DXR is priced at $10.45 on the NASDAQ, while HRC trades at $155.96.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
DXR currently has a P/E ratio of 27.33, whereas HRC's P/E ratio is 41.92. In terms of profitability, DXR's ROE is +0.22%, compared to HRC's ROE of +0.14%. Regarding short-term risk, DXR is more volatile compared to HRC. This indicates higher risk in terms of short-term price fluctuations for DXR.Check HRC's competition here
Antares Pharma, Inc. (NASDAQ: ATRS)
DXR vs ATRS Comparison July 2026
Daxor Corporation (NASDAQ: DXR) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, DXR stands at 52.7M. In comparison, ATRS has a market cap of 0. Regarding current trading prices, DXR is priced at $10.45 on the NASDAQ, while ATRS trades at $5.59.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
DXR currently has a P/E ratio of 27.33, whereas ATRS's P/E ratio is 14.95. In terms of profitability, DXR's ROE is +0.22%, compared to ATRS's ROE of +0.31%. Regarding short-term risk, DXR is more volatile compared to ATRS. This indicates higher risk in terms of short-term price fluctuations for DXR.Check ATRS's competition here
Invuity, Inc. (NASDAQ: IVTY)
DXR vs IVTY Comparison July 2026
Daxor Corporation (NASDAQ: DXR) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, DXR stands at 52.7M. In comparison, IVTY has a market cap of 0. Regarding current trading prices, DXR is priced at $10.45 on the NASDAQ, while IVTY trades at $7.39.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
DXR currently has a P/E ratio of 27.33, whereas IVTY's P/E ratio is -3.80. In terms of profitability, DXR's ROE is +0.22%, compared to IVTY's ROE of -2.40%. Regarding short-term risk, DXR is more volatile compared to IVTY. This indicates higher risk in terms of short-term price fluctuations for DXR.Check IVTY's competition here
Analogic Corporation (NASDAQ: ALOG)
DXR vs ALOG Comparison July 2026
Daxor Corporation (NASDAQ: DXR) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, DXR stands at 52.7M. In comparison, ALOG has a market cap of 0. Regarding current trading prices, DXR is priced at $10.45 on the NASDAQ, while ALOG trades at $83.95.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
DXR currently has a P/E ratio of 27.33, whereas ALOG's P/E ratio is 40.93. In terms of profitability, DXR's ROE is +0.22%, compared to ALOG's ROE of -0.15%. Regarding short-term risk, DXR is more volatile compared to ALOG. This indicates higher risk in terms of short-term price fluctuations for DXR.Check ALOG's competition here